2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 647

Involvement of Peripheral Nervous System in Primary Sjögren Syndrome, a Gessar Analysis
Abstract Number: 2553

Involvement of M2 Macrophages in the Pathogenesis of Arthritis in a Mouse Model
Abstract Number: 932

IRF4-Dependent and IRF4-Independent Pathways Contribute to DC Dysfunction in Lupus
Abstract Number: 3081

IRF5 Deletion Prevents the SLE-like Disease Initiated By Dendritic Cell-Specific Loss of Caspase 8
Abstract Number: 695

Is a Geriatric Rheumatology Sub-Group Worth Distinguishing? Disease Characteristics of a Geriatric Psoriatic Arthritis (Gero PsA) Subgroup Compared with Those of below 45 Years of Age
Abstract Number: 2862

Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review
Abstract Number: 704

Is Axial Involvement Underestimated in Patients with Psoriatic Arthritis? Data from the Bepas Cohort
Abstract Number: 2735

Is Disease Duration an Independent Predictor of Treatment Response Among Patients with Rheumatoid Arthritis Initiating Abatacept?
Abstract Number: 698

Is It Possible to Identify Psoriasis Patients Who Will Develop Axial Disease? Real Life Data from Psart (Psoriatic Arthritis Registry of Turkey)
Abstract Number: 2676

Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective
Abstract Number: 437

Is Mode of Action Important When Switching Biologic Monotherapy in Rheumatoid Arthritis? Drug Adherence Results from the Swedish Ssatg Registry
Abstract Number: 1303

Is MRI More Sensitive Than Conventional Radiographs to Detect Hand Osteoarthritis Progression over 5 Years Follow-up?
Abstract Number: 1316

Is MRI of Use in Identifying Which Undifferentiated Arthritis Patients Will Develop RA?
Abstract Number: 2931

Is Pregnancy a Risk Factor for the Onset of Systemic Lupus Erythematosus (SLE) in Women of the Reproductive Age: A Population Based Case-Control Study?
Abstract Number: 2266

Is Rheumatic Disease Really More Severe in Indigenous Populations? a Systematic Review of Clinical Outcomes in Indigenous Populations of Canada, the United States, Australia and New Zealand

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].